EuBiologics Co., Ltd.

A206650

KR7206650004

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/05/2024 BST			5-day change	1st Jan Change
12,840 ^KRW	-0.47%		-4.89%	+11.94%

01-29	Zimbabwe launches door-to-door cholera vaccination campaign	RE
2023	Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial	CI

EuBiologics Co., Ltd.(KOSDAQ:A206650) added to S&P Global BMI Index

September 23, 2019 at 05:00 am

Latest news about EuBiologics Co., Ltd.

Zimbabwe launches door-to-door cholera vaccination campaign	01-29	RE
Pop Biotechnologies and Eubiologics' Eucorvac-19 Vaccine Hits Target in Phase 3 Trial	14/07/23	CI
EuBiologics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	20/03/23	CI
Eubiologics Co., Ltd. Announces Phase Iii Clinical Trial Ind Approval of Eucorvac-19, Covid-19 Vaccine Candidate, in South Korea	03/02/22	CI
Clips Co., Ltd. announced that it expects to receive KRW 2.50003 billion in funding from EuBiologics Co., Ltd., SK bioscience Co.,Ltd., BNC Korea Co., Ltd.	26/01/22	CI
SK bioscience : S.Korea to begin producing Novavax COVID-19 vaccine as early as June	12/04/21	RE
EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea	21/01/21	CI
EuBiologics Co., Ltd.(KOSDAQ:A206650) added to S&P Global BMI Index	23/09/19	CI
ATGC Co., Ltd. announced that it has received KRW 2.1 billion in funding from EuBiologics Co., Ltd.	09/01/19	CI
ATGC Co., Ltd. announced that it expects to receive KRW 2.1 billion in funding from EuBiologics Co., Ltd.	03/01/19	CI
EuBiologics Co., Ltd. announced that it has received KRW 30.00000351 billion in funding	29/04/18	CI
EuBiologics Co., Ltd. announced that it expects to receive KRW 30 billion in funding	11/02/18	CI
Global Health Investment Fund I, LLC, managed by Global Health Investment Advisors, LLC acquired 6.19% stake in EuBiologics Co., Ltd..	01/02/17	CI
EuBiologics Co., Ltd. has completed an IPO in the amount of KRW 19.2 billion.	19/01/17	CI
EuBiologics Co., Ltd. has filed an IPO.	28/09/16	CI
EuBiologics Co., Ltd. announced that it has received $7.5 million in funding from Hanwha Investment Corp., Korea Investment Partners Co. Ltd., Oxford Bioscience Partners, Lion's Head Global Partners, Investment Arm	26/08/14	CI

EuBiologics Co Ltd is a Korea-based company mainly engaged in the manufacture and sale of biopharmaceuticals. The Company operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
EUBIOLOGICS CO., LTD.	+11.94%	343M
CSL LIMITED	-1.26%	89.46B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.74B
BIOGEN INC.	-9.06%	33.03B
UCB	+55.32%	24.68B
BIOMARIN PHARMACEUTICAL INC.	-16.61%	15.12B
INCYTE CORPORATION	-9.14%	12.81B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.11%	11.79B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.61%	11.64B
SWEDISH ORPHAN BIOVITRUM AB	+7.79%	8.9B

Biopharmaceuticals

EuBiologics Co., Ltd.

Equities

A206650

KR7206650004

Pharmaceuticals

EuBiologics Co., Ltd.(KOSDAQ:A206650) added to S&P Global BMI Index

Latest news about EuBiologics Co., Ltd.

Chart EuBiologics Co., Ltd.

Company Profile

Income Statement Evolution

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Biopharmaceuticals